G

A

GUERCI-BRESLER , Agnès

Last name: GUERCI-BRESLER

First name: Agnès

July 2012 (v1)

Journal article

Metadata-only

Bortezomib combined with low-dose cytarabine in Intermediate-2 and high risk myelodysplastic syndromes. A phase I/II Study by the GFM.

Natarajan-Amé, Shanti Park, Sophie Ades, Lionel

Marrow cells from patients with higher-risk myelodysplastic syndrome (MDS) exhibit constitutive nuclear factor (NF)-κB activation. The proteasome inhibitor, bortezomib, has limited efficacy as a single agent in acute myeloid leukaemia. Its activity on leukaemic cell lines is potentiated by chemotherapy. We treated 43 higher-risk MDS patients...

Uploaded on: December 2, 2022
February 16, 2017 (v1)

Journal article

Metadata-only

Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI study

Rea, Delphine Nicolini, Franck Tulliez, Michel

International audience

Uploaded on: December 4, 2022